In a surprising move, the Trump administration has expanded RSV vaccinations to adults starting at age 50. This decision follows the advice of a recently dismissed government panel and raises questions about public health policies.
A new monoclonal antibody called clesrovimab has been recommended for infants to prevent RSV, stirring debate among health experts and advocates. The FDA approved the treatment just weeks ago.
In a pivotal vote, the CDC's advisory committee has recommended the use of clesrovimab, a new monoclonal antibody, for infants under eight months to combat RSV, marking a significant advancement in public health.
Merck's new drug ENFLONSIA has received FDA approval for preventing RSV in newborns and infants, promising significant reductions in hospitalizations and severe respiratory illness. This long-acting monoclonal antibody offers hope for parents facing RSV season challenges.
A groundbreaking CDC study shows a dramatic decline in RSV hospitalizations for infants, with new vaccines and treatments reducing rates by up to 71%. Discover how these advancements are transforming baby care and preventing severe illness.
A recent analysis reveals a dramatic decrease in RSV-associated hospitalizations among infants aged 0-7 months during the 2024-25 season, thanks to the widespread use of maternal vaccination and nirsevimab. This significant reduction highlights the effectiveness of preventive measures and underscores the importance of early intervention.
Pneumonia poses serious health risks, especially for older adults and young children. Learn how vaccines and lifestyle changes can reduce your risk and keep your immune system strong.
